This website is intended for healthcare professionals only
User log in

Trial log in

Cardiovascular considerations in patients with type 2 diabetes

This promotional module has been initiated, funded and reviewed by Boehringer Ingelheim. The content of this industry-supported learning activity has been generated by Practice Nurse.


The goals of treatment for type 2 diabetes are to prevent or delay complications and maintain quality of life.1 According to international guidelines, this requires control not only of blood glucose levels, but also cardiovascular risk factor management.1

This module looks at the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes, and the role of pharmacotherapy in managing the condition in line with current guidelines.


On completion of this module, you will have a better understanding of:

  • The association between type 2 diabetes and cardiovascular complications
  • Evidence from the cardiovascular outcomes trials of agents used in the management of type 2 diabetes
  • Latest guidance for the pharmacological management of type 2 diabetes
  • The importance of a patient-centred approach to management

This module is one of a series of five. Others in the series are:

This resource is provided at an intermediate level. Read the article and answer the self-assessment questions, and reflect on what you have learned.

Complete the resource to obtain a certificate to include in your revalidation portfolio. You should record the time spent on this resource in your CPD log.


1. Davies MJ, D’Alessio D, Fradkin J. Management of hyperglycemia in T2DM, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669-2701

Job Code: PC-GB-103943

Date of preparation: March 2021

You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI's products, services and events.

Click here for Trajenta (linagliptin) Prescribing Information: Great Britain | Northern Ireland

Click here for Jardiance (empagliflozin) Prescribing Information: Great Britain | Northern Ireland

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).